Preferred Label : Magrolimab;
NCIt definition : A humanized monoclonal antibody targeting the human cell surface antigen CD47, with
potential immunostimulating and antineoplastic activities. Upon administration, magrolimab
selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47
with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic
cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages,
through the induction of pro-phagocytic signaling mediated by calreticulin, which
is specifically expressed on the surface of tumor cells, and results in specific tumor
cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte
immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed
on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface
of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha,
leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby
allowing cancer cells to proliferate.;
UNII : 90YIEHRFJ9;
CAS number : 2169232-81-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2169232-81-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : Hu5F9-G4; ONO-7913;
NCI Metathesaurus CUI : CL474125;
Codes from synonyms : 257;
Origin ID : C117730;
UMLS CUI : C5227415;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
